ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
The world's first-in-class miRNA therapeutics to cure diabetes by pancreatic beta cell regeneration
May 07, 2021Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., has selected its first technological investment target to expand its new bio business. -
Nexturn Bio Inc. decided to invest in the development of a new drug pipeline for diabetes treatment using miRNA
May 07, 2021Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., said it has secured a 50% stake in RosVivo Therapeutics Inc., a U.S. new drug developer, as its first investment destination. RosVivo recently developed RSVI-301, a new drug pipeline that ...
Pharma Sources Insight January 2025
